A Novel Azathioprine Polysaccharide Nanoparticle Enhances the Efficacy of Systemic Lupus Erythematosus Therapy

被引:0
作者
Chandrababu Rejeeth
Nipun Babu Varukattu
Alok Sharma
Raju Suresh Kumar
Abdulrahman I. Almansour
Natarajan Arumugam
机构
[1] Periyar University,Department of Biochemistry
[2] The University of Nebraska Lincoln,Department of Nutrition and Health Sciences
[3] Department of Pharmaceutical Technology,Department of Chemistry, College of Science
[4] Meerut Institute of Engineering and Technology,undefined
[5] King Saud University,undefined
关键词
Systemic lupus erythematosus; Azathioprine; Polysaccharide; Nanoparticles; Drug delivery; Cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Systemic lupus erythematosus (SLE) patients will suffer from some level of discomfort as the disease progresses due to involvement with the respiratory system. Shrinking lung syndrome is an uncommon disease side effect. SLE has traditionally been treated with chemical immunosuppressants. But these chemical drugs have low solubility, a short half-life in circulation, poor solubility, and higher side effects. One of the most effective ways to extend the time of circulation is to combine pharmaceuticals with nanocarriers that are developed. This method is particularly interesting autoimmune disorders have not been widely employed for the treatment of cancer and other infectious diseases. Here, we use a novel biocompatible polysaccharide nanoparticle, effectively synthesizing a simple but universal drug delivery platform. The immunosuppressant azathioprine was initially conjugated onto the polysaccharide nanocarrier in this proof-of-concept trial for the treatment of SLE. The kidneys only cleared the AZA-PHA nanoparticles slowly, and they had a 30% cytotoxicity. Azathioprine-polysaccharide nanoparticles demonstrated greater therapeutic efficacy to azathioprine-polysaccharide nanoparticles in a murine SLE model without significantly increasing toxicity. This delivery method, which might act as a fresh and universal platform, might make it possible to treat SLE.
引用
收藏
页码:2075 / 2082
页数:7
相关论文
共 154 条
[1]  
Amarnani R(2021)Lupus and the lungs: The assessment and management of pulmonary manifestations of systemic lupus erythematosus Front Med (Lausanne) 7 610257-610257
[2]  
Yeoh S-A(2022)Systemic lupus erythematosus and lung involvement: A comprehensive review J Clin Med 11 6714-30
[3]  
Denneny EK(2018)Primary respiratory disease in patients with systemic lupus erythematosus: Data from the Spanish rheumatology society lupus registry (RELESSER) cohort Arthritis Res Ther 20 280-124
[4]  
Wincup C(2020)Immunological pathogenesis and treatment of systemic lupus erythematosus World Journal of Pediatrics 16 19-136
[5]  
Shin JI(2021)Engineering precision nanoparticles for drug delivery Nat Rev Drug Discovery 20 101-94538
[6]  
Lee KH(2013)Cisplatin-functionalized silica nanoparticles for cancer chemotherapy Cancer Nanotechnology 4 127-2059
[7]  
Park S(2015)A novel magnetic drug delivery nanocomplex with a cisplatin-conjugated Fe3O4 core and a PEG-functionalized mesoporous silica shell for enhancing cancer drug delivery efficiency RSC Adv 5 94534-2964
[8]  
Yang JW(2017)Cancer nanomedicine: From PDGF targeted drug delivery MedChemComm 8 2055-805
[9]  
Kim HJ(2022)Design of bio-graphene-based multifunctional nanocomposites exhibits intracellular drug delivery in cervical cancer treatment ACS Appl Bio Mater 5 2956-346
[10]  
Song K(2021)The latest developments in the area of therapeutic delivery excluding some diseases, such as COVID-19 and the big three (HIV/AID, malaria and tuberculosis) Ther Deliv 12 799-4141